OGN Stock Analysis: Buy, Sell, or Hold?
OGN - Organon & Co.
$13.77
0.00 (0.00%)
▲
5d:
+0.07%
30d:
+1.47%
90d:
+2.76%
WAIT
LOW Confidence
Analysis Updated: Sep 3, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: OGN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: OGN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.67
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$8.49
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $13.77, which is considered extended relative to its 30-day fair value range of $13.58 to $13.76. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.8) compared to its historical average (2.8). At these levels, the market is pricing in 11.2% annual earnings growth.
Technical Outlook: Technically, OGN is in a uptrend. The price is currently testing key support at $13.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OGN is in a uptrend. The price is currently testing key support at $13.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.58 -
$13.76
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
44.8%
Protect Your Profits
OGN is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 18.3% above Wall St target ($11.25)
- BULLISH: Expecting earnings turnaround to 11.2% growth with -2.3% revenue growth
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.58 -
$13.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.72
Resistance Level
$13.79
Current Trend
Uptrend
Technical data as of
Sep 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.81
Wall Street Target
$11.25
(-18.3%)
Revenue Growth (YoY)
-2.3%
Earnings Growth (YoY)
-28.3%
Profit Margin
3.4%
Valuation Premium vs History
+11.2% premium
PE vs Historical
3.8 vs 2.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.2%
(market-implied from PE analysis)
1-Year Target
$15.31
(+11%)
2-Year Target
$17.03
(+24%)
3-Year Target
$18.93
(+38%)
3-Yr Target (if PE normalizes)
(PE: 4→3)
PE COMPRESSION
$13.92
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 8.4%)
$93.03
(+576%)
Base:
(SPY PE: 3.8, Growth: 8.4%)
$17.52
(+27%)
Bear:
(PE: 2.8, Growth: 8.4%)
$12.88
(-7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 17.65 | Current EPS (TTM): $0.78
Bull Case
$30.29
(+120%)
Analyst growth 100.0%, PE expands to 19.4
Base Case
$27.54
(+100%)
Market implied 100.0%, PE stable at 17.7
Bear Case
$9.36
(-32%)
Severe decline -20.0%, PE contracts to 15.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 04, 2026 1:42 AM ET
Data refreshes hourly during market hours. Next update: 2:42 AM
Data refreshes hourly during market hours. Next update: 2:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1315 | 47 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 38 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 48 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 47 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$236 | 43 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
